Considerations of Gene Expression Analysis Methods for Gapmer Antisense Oligonucleotide-Treated Samples
- 25 October 2026
- journal article
- research article
- Published by SAGE Publications in Nucleic Acid Therapeutics
Abstract
Probe-based PCR assays are commonly used to evaluate gene expression in antisense oligonucleotide (ASO)-treated samples, but assay design and postextraction processing may introduce substantial measurement bias. We investigated workflow-dependent differences in measured knockdown across PCR-based and RNA-sequencing assays using an allele-specific gapmer ASO, targeting a linked single nucleotide polymorphism of a dominant-negative SPTAN1 variant. Exogenous ribonuclease H (RNase H) activity during reverse transcription or ribosomal RNA (rRNA)-depletion inflated apparent knockdown and reduced RNA-sequencing coverage at the ASO-binding site. In droplet digital PCR (ddPCR), allele-specific detection probes overlapping the ASO-binding site produced substantially greater apparent knockdown than nonoverlapping probes, particularly following workflows with active RNase H. Spike-in experiments showed that this bias was not reproduced by adding ASO to purified RNA before complementary DNA (cDNA) synthesis or to cDNA before ddPCR, but emerged when ASO was present during rRNA depletion. Together, these findings show that exogenous RNase H activity during RNA processing and ASO–probe overlap can distort measurements of gapmer-mediated transcript reduction. Poly(A)-based RNA sequencing, reverse transcriptase with reduced RNase H activity, and nonoverlapping PCR detection probes can minimize measurement bias when evaluating gapmer ASO-mediated knockdown.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (F31NS145565)
- National Human Genome Research Institute (R35HG011311)
This publication has 11 references indexed in Scilit:
- A pervasive RT–qPCR artifact inflates RNA knockdown by RNA-targeting CRISPRNature Biotechnology, 2026
- The utility of ultra-deep RNA sequencing in Mendelian disorder diagnosticsThe American Journal of Human Genetics, 2025
- Clinical validation of RNA sequencing for Mendelian disorder diagnosticsThe American Journal of Human Genetics, 2025
- Challenges of Assessing Exon 53 Skipping of the Human DMD Transcript with Locked Nucleic Acid-Modified Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular DystrophyNucleic Acid Therapeutics, 2023
- Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense OligonucleotidesNucleic Acid Therapeutics, 2022
- Nonsense mutations in alpha-II spectrin in three families with juvenile onset hereditary motor neuropathyBrain, 2019
- Using Droplet Digital PCR to Analyze Allele-Specific RNA Expression2018
- Molecular Mechanisms of Antisense OligonucleotidesNucleic Acid Therapeutics, 2017
- Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotidesNucleic Acids Research, 2014
- Modulation of Lipoprotein Metabolism by Antisense Technology: Preclinical Drug Discovery Methodology2013